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ment regimens for chronic myeloid leukemia. If further research were funded, stud-
ies should examine a combination of natural history, treatment, and quality of life 
parameters, especially the effectiveness of first-line TKI treatment.
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Objectives: The first goal was to adapt an existing Austrian decision-analytic 
model for chronic myeloid leukemia (CML) treatment to the US-American health 
care context. Secondly, we updated the model with new data and further treat-
ment strategies to identify the most effective and most cost-effective strategy for 
the treatment of CML patients with different sequential tyrosine kinase inhibi-
tors (TKIs). MethOds: We evaluated 18 different treatment strategies within the 
US-American setting in terms of survival, quality-adjusted survival and costs. For 
model parameters, data from literature, a US-American expert survey, the Utah 
Cancer Registry, and economic data from a US-American database were used. 
Evaluated treatment strategies included imatinib, dasatinib, nilotinib, bosutinib, 
ponatinib, stem-cell transplantation and chemotherapy. The Markov state-tran-
sition model was analyzed as a cohort simulation over a lifelong time horizon, 
a third-party payer perspective was adopted and a discount rate of 3% was used. 
Additionally, several deterministic and probabilistic sensitivity analyses were con-
ducted. Results: Imatinib without second-line TKI resulted in an incremental 
cost-utility ratio (ICUR) of $148,700/QALY gained (incremental cost-effectiveness 
ratio (ICER) of $128,800/Lys) compared to baseline strategy ‘chemotherapy’. Imatinib 
with second-line nilotinib yielded an ICUR of $217,100/QALY gained (ICER $242,200/
LY) compared to imatinib without second-line TKI. Imatinib followed by second-
line bosutinib had an ICUR of $331,300/QALY gained (ICER $265,100/LY) compared 
to imatinib followed by second-line nilotinib. Imatinib with second-line dasatinib 
produced an ICUR of $343,200/QALY gained (ICER $279,600/LY) compared to imatinib 
with second-line bosutinib. All remaining strategies were excluded due to domi-
nance. ICURs and ICERs obtained from the probabilistic sensitivity analysis deviated 
up to 6.5% (2.5%) compared to base-case ICURs (ICERs). cOnclusiOns: Based on 
our analysis and current treatment guidelines, we recommend imatinib followed 
by second-line nilotinib as the most cost-effective treatment strategy. Our model 
results may support clinicians and patients in CML treatment decision making.
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Objectives: To assess the cost-effectiveness of using brentuximab vedotin (BV) in 
treating relapsed or refractory Hodgkin Lymphoma compared to standard chemo-
therapy and allogeneic stem cell transplant in the Swedish health care setting. 
Brentuximab vedotin is a novel antibody drug conjugate targeting CD-30 and is 
indicated for treating relapsed/refractory Hodgkin Lymphoma. MethOds: A Markov 
model with a lifetime horizon was constructed to compare BV to chemotherapy or 
allogeneic stemcell transplant (alloSCT). The analysis had a societal perspective 
and included lost productivity using a human capital approach. The model uses 
comparators relevant to Sweden and all epidemiological and cost parameters were 
based on Swedish sources. Both costs and effects were discounted at 3% according 
to Swedish guidelines. Clinical effectiveness for BV was based on pivotal clinical 
trial results and published data from the literature for the comparators relevant to 
the reimbursement authorities and to enable long term modelling. Outcomes were 
measured in QALYs. Uncertainty was addressed both through probabilistic sensi-
tivity analysis and one-way analyses of central variables. Results: Brentuximab 
vedotin dominated alloSCT (i. e a lower treatment cost and a better health outcome) 
and the ICER when compared to chemotherapy was SEK 419 000 (€ 47 000). One-way 
sensitivity analyses showed that the results were stable when central variables 
were varied. The probabilistic analysis also showed that brentuximab vedotin had 
a high probability of being the most cost-effective treatment at the accepted thresh-
old values for all scenarios. cOnclusiOns: The ICERs calculated were all below 
commonly accepted willingness to pay for a QALY in Sweden for both comparator 
scenarios. Brentuximab vedotin is a cost effective treatment option for relapsed/
refractory Hodgkin Lymphoma in the Swedish health care setting.
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Objectives: This study estimated the cost-utility of axitinib after sunitinib failure 
in adult patients with renal cell carcinoma. Total costs and quality adjusted life 
years accrued with axitinib was compared to everolimus, the only drug for second 
line treatment financed by the Portuguese National Health Service. MethOds: 
A 4-week cycle Markov model with three health states (progression free, post 
progression, and death) was adapted to the Portuguese setting. In the absence of 
head-to-head clinical trials and the unfeasibility of a standard indirect comparison, 
relative efficacy was based on a previous simulated treatment comparison. Axitinib 
trial data on quality of life (utility) was used for the progression free stage and 
Objectives: To identify the dominant scheme of mRCC second-line target treat-
ment (compare two alternatives – Axitinib and Everolimus). MethOds: Based on 
the Markov model, the cost-effectiveness analysis was realized. Overall survival, 
annual survival rate, time to progression of disease and direct cost of mRCC treat-
ment was evaluated. Costs analysis included: costs of two target therapy lines 
(Sunitinib as a first-line in combination with Axitinib or Everolimus treatment); cost 
of 3 and 4 grade side effects compensation; cost of diagnosis and inpatient care; cost 
of disease progression; cost of palliative and best supportive care. Results: During 
the pharmacoeconomic analysis of Axitinib use as a second-line therapy for mRCC, 
it was found that this target therapy regimen would significantly increase the time 
to progression and the overall survival which amounted to 22,75 months, with an 
annual survival rate of 68%, 38% and 17% of patients following the first, second and 
third year of treatment, respectively. Despite the high cost of this treatment regimen, 
reaching 51.327 EUR at the horizon of ten year study, the treatment regimen includ-
ing Axitinib will be characterized by the lowest values of the cost-effectiveness 
ratio, reflecting the costs incurred by the health care system for patient’s life sav-
ing, and incremental cost-effectiveness ratio, which was less than willingness to 
pay threshold in Russia. cOnclusiOns: It is shown, Axitinib use as second-line 
of target therapy in patients with mRCC is the most preferable treatment regimen 
then Everolimus from the pharmacoeconomic point of view.
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Objectives: Demonstrate through an economic evaluation of cost-effectiveness 
that using Hydralazine LP magnesium valproate (Transkrip ®) associated with 
first-line chemotherapy in the treatment of persistent or recurrent metastatic 
stage IVB cervical cancer, type not candidates for surgery or radiotherapy is more 
effective than the alternatives available in Mexican health institutions: cisplatin 
with topotecan (CT), cisplatin with paclitaxel (CP), cisplatin with vinorelbine (CV), 
carboplatin with paclitaxel (CaP), paclitaxel (P), cisplatin and cisplatin with gem-
citabine © (CG). MethOds: A cost-effectiveness analysis was developed, using 
a Markov model with a time horizon of 2 years divided into 24 monthly cycles, 
the measure of effectiveness was determined as the years gained free survival 
(PFS), being an advanced cancer is significant, only were measured direct medi-
cal costs, an analysis of incremental cost-effectiveness was performed. To test 
the robustness of the model a deterministic and probabilistic sensitivity analysis 
was performed. Results:  The cost per patient using therapy with hydralazine LP 
magnesium valproate (Transkrip ®) is $ 142,109.93, gaining 0.8846 years in 
Progression free survival this treatment was more effective but more expensive, 
paclitaxel had a cost of $ 26,988.64 with 0.3631 years in PFS, this therapy is less 
expensive but more effective than all comparators. The ICER of (Transkrip ®) was 
$ 220.757 pesos per year in PFS versus paclitaxel. cOnclusiOns: The economic 
results of treatment of patients with metastatic cervical cancer, through an epige-
netic therapy with hydralazine LP magnesium valproate (Transkrip ®) over a time 
horizon of two years showed that hydralazine LP magnesium valproate (Transkrip 
®) is a cost effective alternative respect to comparators showed a greater response 
in years of progression-free survival and ICER below of 2 GDP.
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Objectives: Value-of-Information analysis can help to guide decision about future 
research priorities: If and what further research is needed? Our aim was to guide 
decision regarding future outcomes research on parameters related to different 
regimens for chronic myeloid leukemia (CML). MethOds: We updated a previously 
developed state-transition Markov model of CML, which evaluates seven treatment 
regimens including tyrosine kinase inhibitors, chemotherapy and stem cell trans-
plantation (SCT). We derived model parameters from published trials data, Austrian 
clinical, epidemiological, and economic data. We performed a cohort simulation over 
a lifetime horizon, adopted a societal perspective, and discounted costs and benefits 
at 3% annually. We calculated the expected value of perfect information (EVPI), 
partial perfect information (EVPPI), and the population EVPI (PEVPI). Additionally, 
we examined the expected value of sample information (EVSI) for different trial 
sizes. Results: Three strategies are on the efficiency frontier: imatinibàchemo-
therapy/SCT, nilotinibàchemotherapy/SCT (140,000 € /QALY) and nilotinibàdasat-
inibàchemotherapy/SCT (176,000 € /QALY). The EVPI for eliminating all uncertainty 
resulted in a curve with two peaks. One peak is around a WTP threshold of 150,000 
€ /QALY (EVPI 4,600 € ) and another peak is at 180,000 € /QALY (EVPI 7,700 € ). The PEVPI 
for Austria assuming a 10-year technology horizon was 2.5 million € (WTP 150,000 
€ /QALY) and 4.5 million € (WTP 180,000 € /QALY). EVPPI identified four parameters 
most responsible for decision uncertainty: duration of first-line therapy, probability 
of progressing from chronic phase to accelerated phase, probability of receiving a 
SCT, and the health-utility after SCT. The EVSI commented on the optimal study 
size for these parameters given the cost of obtaining information. cOnclusiOns: 
Acquiring additional evidence could prove valuable for determining optimal treat-
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Objectives: Metastatic melanoma has a poor prognosis with 10 year survival 
being < 5%. Standard therapy is the effective but costly Ipilimumab. An emerging 
1st line treatment is Tumor Infiltrating Lymphocytes (TIL), with response rates 
> 50% and expected survival rates of 25%-42% versus 45% (1yr) and 23,5% (2yr) for 
Ipilimumab. TIL is highly personalized, however complex and requests substantial 
upfront investments from the hospital in expensive lab-equipment, staff expertise 
and training, as well as extremely tight hospital logistics. Therefore, an early health 
economic modelling study, supporting a Coverage with Evidence Development (CED) 
program, was performed. MethOds: We used a Markov decision model to estimate 
the expected costs and outcomes (quality adjusted life years; QALYs) for TIL ver-
sus Ipilimumab in metastatic melanoma patients from a societal perspective over 
a life long time horizon. Three mutually exclusive health states (stable disease, 
progressive disease and death) were modelled, divided in first and second line 
treatment. Technical failures and non-compliance were incorporated to reflect the 
dynamic nature of the technology. To inform further research prioritization, Value 
of Information (VOI) analysis was performed. Results: TIL is expected to yield 
more QALYs compared to Ipilimumab (0.99 vs 0.52 respectively) at lower total costs 
(€ 83,588 vs € 87,834 respectively). Based on current information TIL has a probability 
of 88% for being cost effective at a cost/QALY threshold of € 30,000. Expected Value of 
Perfect Information (EVPI) amounted to € 1,2 million. Partial EVPI (EVPPI) was highest 
for survival data (€ 550,000). Expected Value of Sample information was estimated 
€ 355,000 for an optimal sample size of n= 50. cOnclusiOns: TIL is expected to 
improve QALYs compared to Ipilimumab at lower incremental cost and has the 
highest probability of being cost-effective. To reduce decision uncertainty, a future 
clinical trial to investigate survival seems most valuable, and should preferably be 
undertaken as part of a CED program.
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Objectives: This study assessed the cost-effectiveness of everolimus versus axi-
tinib for the treatment of advanced metastatic renal cell carcinoma (mRCC) in the 
United Kingdom (UK). MethOds: A Markov model was developed with three health 
states: stable disease, disease progression and death. The model time horizon was 
12 years and a UK NHS perspective was considered. There are no head to head stud-
ies comparing everolimus with axitinib, thus evidence from a weighted adjusted 
indirect analysis based on the RECORD-1 and AXIS trials was used to compare 
progression-free survival (PFS) for everolimus versus axitinib. Survival distributions 
for PFS were fitted to the post-matched population and fit statistics were generated. 
As overall survival (OS) data were not available from the AXIS trial at the time of 
the indirect analysis, the model assumed that the OS for axitinib was equivalent 
to that of everolimus, based on OS from the RECORD-1 trial. The Weibull survival 
distribution was used for both PFS and OS. Quality of life data were derived from 
the Swinburn et al. study and drug costs were obtained from the British National 
Formulary. Results: Everolimus resulted in a progression-free life expectancy 
of 0.60 years compared to 0.57 with axitinib. Everolimus resulted in 0.65 QALYs 
compared to 0.63 QALYs for axitinib. Active drug costs were £8,105 for everolimus 
and £25,723 for axitinib. Total costs were higher for axitinib (£42,533) compared 
to everolimus (£24,387). The cost difference reflects the higher treatment costs 
per month and longer treatment duration for axitinib compared to everolimus. 
Therefore, the incremental cost of axitinib compared with axitinib was -£18,146, 
highlighting that everolimus is less expensive. The incremental cost per QALY 
gained was -£1,048,954. cOnclusiOns: This cost-effectiveness analysis demon-
strates that everolimus likely dominates axitinib, i.e. it is more effective and less 
expensive compared with axitinib in the treatment of mRCC.
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Objectives: To conduct an economic evaluation comparing Herceptin subcu-
taneous formulation (Herceptin-SC) with -Herceptin intravenous formulation 
(Herceptin-IV), in the treatment of patients with human epidermal growth factor 
receptor 2-positive (HER2+) early and metastatic breast cancer (EBC-MBC), in the 
Greek health care setting. MethOds: A cost-minimization model was developed 
to compare the total cost of care, from the hospital perspective, for new and existing 
patients, over 18 cycles therapy course. Total cost of therapy reflects drug acquisition 
cost, consumables dispensed, hospital overheads, physician and other staff time. 
Costing data were obtained from official Government sources (in 2014) and resource 
utilization data from a local validation of an international time and motion study. 
Due to the short time horizon of the study, costs were not discounted. Results: 
The mean total cost of therapy per patient on Herceptin-IV was estimated at 
€ 24,163 compared to € 23,042 per patient receiving Herceptin-SC. Drug acquisition 
costs accounted for € 22,630 and € 22,579 of total therapy costs for Herceptin-IV and 
Herceptin-SC, respectively. Following drug acquisition costs, the administration cost 
was € 518 and € 161 for Herceptin-IV and Herceptin-SC, respectively. Moreover, the 
central venous access device cost was € 290 and € 0 of the total costs of Herceptin 
IV and Herceptin SC, respectively. Finally, overhead costs made up approximately 
€ 725 of the total cost for Herceptin-IV and € 302 for Herceptin-SC. Sensitivity analy-
sis showed that the results of the model were sensitive to drug acquisition costs 
and patient weight. cOnclusiOns: The cost of treatment with Herceptin-SC is 
assumed equal for everolimus, while utilities for the post progression stages were 
obtained from the literature. Resource use was determined by a panel of five expe-
rienced experts to reflect Portuguese clinical practice. Official unit costs were used, 
following the Portuguese National Health Service perspective. The model adopted 
a lifetime frame (15 years) with a 5%discount rate. Results: Axitinib allowed an 
increment of 0.20 years of progression free survival, 0.53 years of overall survival, 
and 0.32 quality adjusted life years compared to everolimus. Despite having a similar 
daily cost, the use of axitinib implied an incremental cost of 9,100€ , mainly due to 
the increase in progression free survival, that matches second line treatment dura-
tion. Consequently the cost per quality adjusted life year was 28,598€ . Sensitivity 
analyses showed that results were robust to model parameters specification, 
with the main uncertainty source being clinical efficacy. cOnclusiOns: Axitinib 
increased progression free and overall survival, which allowed patients to benefit 
from more quality adjusted life years at a cost increase. Overall, it was possible to 
advocate that axitinib is cost-effective, as the cost per QALY is below commonly 
accepted thresholds.
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Objectives: Clinical studies have shown that docetaxel to be superior to paclitaxel 
in overall survival (OS) and progression free survival (PFS) (median OS: 1.28 vs 1.06 
year; median PFS: 0.47 vs 0.30 year) for the treatment of patients with metastatic 
breast cancer progressing after an anthracycline-based regimen. Other studies 
have shown paclitaxel-albumin extended OS by 9.7 weeks, and TTP by 4 weeks. An 
economic evaluation based on these two clinical trials was performed to compare 
paclitaxel albumin, paclitaxel, and docetaxel as a second line treatment for meta-
static breast cancer. MethOds: A Markov model was conducted using three health 
states: PFS, progressed, and death to estimate overall survival, cost, life year gain 
(LYG) and quality adjusted life year (QALY). Efficacy data for the treatments were 
obtained from the published literature. In the absence of head-to-head trials, com-
parative efficacy and safety of taxanes were estimated using indirect comparisons. 
A 3% discount rate for cost and outcomes was used. Cost of chemotherapy, admin-
istering, monitoring the disease, loss of productivity, and adverse drug reactions for 
patients on treatment were included from the US societal perspective. Results: 
Compared to docetaxel, paclitaxel albumin was found to be less expensive ($36,241 
vs $73,510) and more effective in term of QALYs (0.782 vs 0.710). The incremental cost 
effectiveness ratio (ICER) for paclitaxel albumin compared to paclitaxel was $77,670/
QALY. The probabilistic sensitivity analysis showed that paclitaxel albumin has 70% 
probability of being cost effective at $100,000/QALY threshold value. cOnclusiOns: 
Paclitaxel-albumin is an attractive treatment option for the treatment of metastatic 
breast cancer in patients who have failed 1st-line treatment for metastatic disease. 
The primary analysis comparing paclitaxel albumin to docetaxel demonstrated 
that paclitaxel albumin dominated docetaxel because it was less costly and more 
effective.
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Objectives: Whole-breast external beam radiotherapy (EBRT) is normally given 
over 3-6 weeks after lumpectomy in early breast cancer patients to reduce recur-
rence and mortality. An individualised risk-adapted approach to adjuvant radiother-
apy has been tested in the randomised TARGIT-A trial which tested the efficacy of 
one dose of radiation to tumour bed during lumpectomy. The objective of the present 
study was to assess the cost effectiveness of TARGIT-A in these patients. MethOds: 
A model based economic evaluation compared single dose TARGIT-A with current 
practice of EBRT in UK. A state transition Markov model approach was used to 
simulate the treatment outcomes in a time horizon of 20 years post-surgery. The 
primary outcome of interest was quality adjusted life years gained (QALY) and 
analysis was conducted from the health care payer’s perspective. To address deci-
sion uncertainty, probabilistic sensitivity analysis was performed. A discount rate 
of 3.5% was applied to future costs and effects. Results: In the Base Case Analysis 
TARGIT-A was a dominant strategy yielding higher QALYs at a lower cost than EBRT. 
Discounted EBRT and IORT costs for the time horizon of 20 years were £ 20,926 and £ 
14,461 respectively. Discounted incremental QALY gained by use of IORT was 0.0069. 
Model results were robust to parameter uncertainty and probabilistic results were 
similar to the deterministic results. Application of the net monetary benefit (NMB) 
framework revealed higher NMB for TARGIT-A in all Monte Carlo simulations. Cost 
effectiveness acceptability curves show that TARGIT-A is cost effective at various 
willingness to pay thresholds. cOnclusiOns: TARGIT-A is a cost effective strat-
egy to treat early breast cancer patients in the UK. Implementation of this one-off 
radiation treatment within a risk-adapted approach could improve quality of life 
by sparing them from the protracted course of EBRT, improve compliance, prevent 
unnecessary mastectomies and save valuable NHS resources.
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